Turn Therapeutics Inc.
NASDAQ:TTRXBiotechnology
-$0.17 today
- Market cap
- $271.79M
- Beta
- 2.77
- P/E (TTM)
- -45.0
- EPS (TTM)
- -$0.13
Volume 0.05M
Average 0.04M
TTRX Other Current Liabilities
Short-term obligations not reported separately, such as accrued expenses.
Turn Therapeutics Inc.NASDAQ: TTRX
Other Current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Other current liabilities of $2.77M in Q1 FY2026
Q1 FY2026 other current liabilities was $2.77M.
Context
- Other current liabilities amounted to 14.8% of total assets at the end of Q1 FY2026.
- Other current liabilities increased in 2 of the last 2 fiscal years.
- FY2025 was the highest annual figure in the 3 fiscal years shown.
Sources:Balance SheetText generated from reported figures; not investment advice.
Other Current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 3.03M USD
- Year-over-year change
- +353.8%
- 2-year CAGR
- +155.3%
| Period | Period end | Other Current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 3.03M | +353.8% |
| FY2024 | 2024-12-31 | 667.27K | +43.6% |
| FY2023 | 2023-12-31 | 464.62K | — |
Other Current Liabilities vs competitors
How TTRX compares with its peers on the latest reported figures
- TTRX's Mar 2026 other current liabilities of $2.77M is the 5th highest of the 9 companies compared; the peer median is $2.12M.
- Other current liabilities amounts to 14.8% of total assets for TTRX, versus a peer median of 1.2%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $28.15M | -74.2% | -6.4% | 15.1% | |
| Mar 2026 | $5.18M | +1598.1% | — | 49.3% | |
IRDOpus Genetics, Inc. | Mar 2026 | $4.12M | -67.6% | — | 6.2% |
| Mar 2026 | $3M | +101.8% | -3.9% | 1.1% | |
TTRXTurn Therapeutics Inc. | Mar 2026 | $2.77M | — | — | 14.8% |
| Mar 2026 | $1.23M | -62.3% | — | 0.7% | |
| Mar 2026 | $498K | -17.0% | +21.7% | 1.4% | |
| Mar 2026 | $197.59K | -86.4% | +31.2% | 0.7% | |
| Apr 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding TTRX) | $2.12M | -62.3% | +8.9% | 1.2% | |
Competitors are the stored peer set for TTRX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Turn Therapeutics Inc.
NASDAQ:TTRX
Intrinsic Alpha fair value
Locked
Current Price
$8.89
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.